Table 3.
Summary of Kaplan-Meier Analyses
| Prognostic Marker | Log-rank p-value | Total number | Events |
|---|---|---|---|
| Non-Stratified | |||
| IGF1R | 0.018* | 233 | 19 |
| SphK1 | 0.427 | 233 | 19 |
| IGF1R/SphK1 | 0.028* | 232 | 19 |
| pIGF1R | 0.303 | 232 | 19 |
| pIGF1R/SphK1 | 0.118 | 232 | 19 |
| ER-positive | |||
| IGF1R | 0.048* | 165 | 11 |
| SphK1 | 0.250 | 165 | 11 |
| IGF1R/SphK1 | 0.051 | 165 | 11 |
| ER-negative | |||
| IGF1R | 0.445 | 68 | 8 |
| SphK1 | 0.675 | 68 | 8 |
| IGF1R/SphK1 | 0.582 | 68 | 8 |
| Anti-Endocrine Therapy (AET) | |||
| AET-positive vs. AET-negative | 0.006* | 190 | 17 |
| AET-positive | |||
| IGF1R | 0.028* | 190 | 17 |
| SphK1 | 0.101 | 190 | 17 |
| IGF1R/SphK1 | 0.034* | 190 | 17 |
| HER2-negative | |||
| IGF1R | 0.074 | 143 | 4 |
| SphK1 | 0.052 | 143 | 4 |
| pIGF1R | 0.273 | 142 | 4 |
| HER2-positive | |||
| IGF1R | 0.195 | 86 | 14 |
| SphK1 | 0.062 | 86 | 14 |
| pIGF1R | 0.858 | 86 | 14 |
| PR-negative | |||
| IGF1R | 0.290 | 81 | 10 |
| SphK1 | 0.296 | 81 | 10 |
| pIGF1R | 0.410 | 81 | 10 |
| PR-positive | |||
| IGF1R | 0.101 | 147 | 8 |
| SphK1 | 0.293 | 147 | 8 |
| pIGF1R | 0.588 | 146 | 8 |
High vs. low prognostic marker expression *p-value significant; ≤0.05